Fennec Pharma FY2023 PEDMARK sales $21.3M, Q4 net loss $2.7M; $43M licensing deal bolsters cash

FENNEC PHARMACEUTICALS INC.

FY2023 PEDMARK net product sales $21.3M (vs $1.5M in 2022); Q4 net sales $9.7M.
Net loss for FY2023 $16.0M ($0.60 per share) vs $23.7M ($0.90) in 2022; Q4 net loss $2.7M ($0.10).
Cash and equivalents $13.2M at Dec 31, 2023; pro forma cash >$55M after receiving ~$43M upfront from Norgine licensing deal.
Entered exclusive licensing agreement with Norgine for PEDMARQSI in Europe, Australia, NZ; potential up to ~$230M milestones plus tiered royalties.
FDA issued public reminder that PEDMARK is not substitutable with other sodium thiosulfate products.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

FENNEC PHARMACEUTICALS INC. reported financial results for full year and fourth quarter 2023.

Period: full year and fourth quarter 2023
Result: reported results

Exact text from the filing

Fennec Pharmaceuticals Inc. issued a news release announcing full year and fourth quarter financial results for the period ended December 31, 2023.

View on SEC.gov

493 earnings releases filed in the last 30 days. Browse all earnings releases →

FENNEC PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-038444

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.